ISKS Study Links Heritable Defects With Predisposition to Sarcomas
March 1st 2023R. Lor Randall, MD, FACS, discusses how sarcoma experts from around the world connected to collaborate on the ISKS, the importance of identifying and better understanding sarcoma subgroups, and how these findings could inform prescreening for those at risk for the disease.
Read More
Bevacizumab Plus TAS-102 Elicits Survival Improvements in Third-line mCRC
February 24th 2023Bevacizumab plus trifluridine/tipiracil demonstrated improved overall survival and progression-free survival vs TAS-102 alone as third-line treatment for patients with refractory metastatic colorectal cancer.
Read More
TTFields With Chemotherapy Under Investigation in Locally Advanced Pancreatic Cancer
February 23rd 2023Tumor treating fields concomitant with gemcitabine and nab-paclitaxel is being compared with chemotherapy alone in the frontline treatment of patients with aggressive, locally advanced pancreatic cancer as part of the phase 3 PANOVA-3 trial.
Read More
Zanidatamab Plus Chemo Displays Early Activity in HER2+ Metastatic Gastroesophageal Adenocarcinoma
February 22nd 2023The combination of zanidatamab and standard chemotherapy demonstrated activity when used as a first-line treatment for patients with HER2-positive metastatic or advanced gastroesophageal adenocarcinoma.
Read More
PSMA-PET Highlights Evolution of Molecular Imaging in Prostate Cancer
February 21st 2023Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.
Read More
First-line Avelumab Maintenance Under Real-world Evaluation in Metastatic Urothelial Carcinoma
February 20th 2023The baseline characteristics, treatment patterns, and responses to first-line platinum-based chemotherapy for patients with locally advanced or metastatic urothelial carcinoma receiving avelumab maintenance therapy were consistent with responses to usual therapy paradigms in the first-line induction setting.
Read More
RxPONDER Analysis Reveals Racial Disparities in HR+/HER2– Breast Cancer
February 15th 2023Yara Abdou, MD, discusses the racial and clinical analysis of the RxPONDER trial, the need to further investigate the factors that create racial disparities in breast cancer, and the importance of enrolling minority populations onto clinical trials.
Read More
Long-term Data for Niraparib Support Continued Use of PARP Inhibitors in HRD+ Ovarian Cancer
February 14th 2023Dario R. Roque, MD, discusses incorporating PARP inhibitors into practice for patients with homologous recombination deficient ovarian cancer, the role of PARP inhibitors for patients with homologous recombination–proficient ovarian cancer and the expanding investigation of mirvetuximab soravtansine in ovarian cancer.
Read More
Pembrolizumab Plus Total Neoadjuvant Therapy Improves Long-Term OS in Locally Advanced Rectal Cancer
February 13th 2023Thomas J. George, MD, FACP, highlights the long-term data from the NRG-GI002 trial, the next steps for exploring subsets of patients who may benefit from the addition of pembrolizumab or veliparib to total neoadjuvant therapy, and what the use of total neoadjuvant therapy has meant for patients with stage II/III locally advanced rectal cancer.
Read More
Encorafenib Plus Cetuximab With Nivolumab Under Investigation in BRAF V600E–Mutant mCRC
February 9th 2023Investigators in the phase 2 SWOG S2107 trial are evaluating encorafenib plus cetuximab and nivolumab for patients with previously treated, microsatellite stable, unresectable, or metastatic colorectal cancer harboring a BRAF V600E mutation.
Read More
Herbst Highlights the Implications of the FDA Approval of Adjuvant Pembrolizumab in NSCLC
February 9th 2023Roy S. Herbst, MD, PhD, discussed the data that supported the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer, highlighted the implications of the approval for the paradigm, and outlined further research opportunities.
Read More
XL092 Plus Atezolizumab Vs Regorafenib Under Investigation in MSS/MSI-Low mCRC
February 7th 2023The safety and efficacy of a combination regimen comprised of XL092 and atezolizumab is being compared with that of regorafenib monotherapy in patients with microsatellite stable or microsatellite instability–low metastatic colorectal cancer who have progressed on or are intolerant to standard-of-care therapy.
Read More
Socioeconomic Factors Are Associated With Disparities in Germline Testing in Pancreatic Cancer
February 5th 2023Daniel King, MD, PhD, discusses the results of an institutional review evaluating socioeconomic factors associated with disparities for germline genetic testing in patients with pancreatic adenocarcinoma, why germline testing is necessary for thi population, and how he is addressing gaps in germline testing in his own practice.
Read More
NRG/RTOG 1112 Trial Highlights Benefit of Adding SBRT to Sorafenib in Locally Advanced HCC
February 2nd 2023Laura Dawson, MD, FRCPC, discusses data from the NRG/RTOG 1112 trial examining the addition of stereotactic body radiation therapy to sorafenib, the implications of the data for the locally advanced hepatocellular carcinoma treatment paradigm, and next steps for research.
Read More
MRI-Guided SBRT Could Represent Safer, More Precise Radiotherapy Option for Prostate Cancer
February 2nd 2023Amar U. Kishan, MD, discusses the safety results of MRI-guided SBRT compared with the current standard of care, highlights the benefits of using an MRI to guide radiation for patients with prostate cancer, and explains other areas where MRI-guided SBRT could explored.
Read More
Mitul Gandhi, MD, discusses the rationale of combining brentuximab vedotin, nivolumab, dacarbazine, and doxorubicin for patients with early-stage classic Hodgkin lymphoma, the key findings from part C of the SGN35-027 trial, and the next steps for investigating this combination.
Read More
Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the use of trastuzumab emtansine plus radiation in patients with early-stage HER2-positive breast cancer.
Read More
Shaji Kumar, MD, discusses the MAIA trial; key takeaways regarding the long-term safety and efficacy of daratumumab, lenalidomide, and dexamethasone, in transplant-ineligible patients with newly diagnosed multiple myeloma; and the implications of this research on clinical practice.
Read More
Accuracy of Sentinel Lymph Node Biopsies Are Vital to Inform Treatment Decisions in Breast Cancer
January 27th 2023The evolving treatment landscape across breast cancer has escalated the need for the accuracy of sentinel lymph node biopsies following treatment with neoadjuvant chemotherapy to correctly inform subsequent treatment decisions for patients.
Read More
Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response
January 24th 2023David Siegel, MD, PhD, discusses the evaluation of idecabtagene vicleucel in cohort 2C of the KarMMa-2 trial and what these data could mean for this population and others with multiple myeloma.
Read More
Pembrolizumab Following ASCT Generates Promising PFS in T-cell Non-Hodgkin Lymphoma
January 23rd 2023Craig Sauter, MD, discusses the rationale for investigating maintenance pembrolizumab following autologous stem cell transplant in patients with T-cell NHL and explained some of the potential challenges of investigating this regimen in a larger prospective trial in this patient population.
Read More
IK-175 Monotherapy or Plus Nivolumab Shows Early Activity in Urothelial Cancer
January 22nd 2023IK-175 was found to be well tolerated in patients with advanced solid tumors and to elicit responses in those with urothelial cancer when used alone or in combination with nivolumab, according to initial data from an ongoing phase 1a/b study.
Read More